Deconstructing Pancreas Development to Reconstruct Human Islets from Pluripotent Stem Cells  by McKnight, Kristen D. et al.
Cell Stem Cell
PerspectiveDeconstructingPancreasDevelopment toReconstruct
Human Islets fromPluripotent StemCellsKristen D. McKnight,1 Pei Wang,1 and Seung K. Kim1,2,3,*
1Department of Developmental Biology
2Department of Medicine (Oncology Division)
3Howard Hughes Medical Institute
Stanford University School of Medicine, Stanford, CA 94305-5329, USA
*Correspondence: seungkim@stanford.edu
DOI 10.1016/j.stem.2010.03.003
There is considerable excitement about harnessing the potential of human stem cells to replace pancreatic
islets that are destroyed in type 1 diabetes mellitus. However, our current understanding of the mechanisms
underlying pancreas and islet ontogeny has come largely from the powerful genetic, developmental, and
embryological approaches available in nonhuman organisms. Successful islet reconstruction from human
pluripotent cells will require greater attention to ‘‘deconstructing’’ human pancreas and islet developmental
biology and consistent application of conditional genetics, lineage tracing, and cell purification to stem cell
biology.Introduction
In type 1 diabetes mellitus (T1DM), autoimmune destruction of
pancreatic islets of Langerhans leads to a lifelong requirement
for insulin replacement to maintain adequate metabolic homeo-
stasis. However, despite nearly a century of progress, current
replacement regimes represent approximations of insulin control
by native islet b cells, the sole source of insulin. Thus, T1DM is
complicated by accumulated damage to tissues and organs
like blood vessels, neurons, kidneys, and eyes and by premature
mortality.
Advances in our understanding of the mechanisms of
pancreas and islet development, the beguiling possibilities of
stem cell biology, and improvements in islet function after trans-
plantation have served as landmarks for many research teams
and funding programs devoted to developing T1DM therapies.
Several routes toward islet replacement (for brevity we use this
term to encompass efforts to produce islets in vitro or in vivo,
independent of cell source or developmental mechanism) have
been suggested by recent research findings, principally in
mice. These include regeneration, proliferation, transdifferentia-
tion, and transdetermination to increase b cell numbers, and
are reviewed elsewhere (Bouwens, 2006; Zhou et al., 2008;
Puri and Hebrok, 2010). For T1DM, concrete advances in immu-
nosuppression are an obligatory therapeutic ‘‘partner’’ for any
envisioned cell-based therapy and are also reviewed elsewhere
(Cernea and Pozzilli, 2008; Eizirik et al., 2009).
Here we focus on prospects for the use of pluripotent stem
cells such as human embryonic stem cells (ESCs) or induced
pluripotent stem cells (iPSCs) and knowledge about human
pancreas development to create functional cells resembling
human islet b cells or their progenitors. Many aspects of applying
ESC or iPSC biology toward the goal of pancreas cell replace-
ment have also been reviewed recently (Mayhew and Wells,
2010; Robbins et al., 2010; Van Hoof et al., 2009). Our discussion
specifically highlights the need for intensified studies of human
pancreas and islet developmental biology and the rigorous appli-
cation of developmental biology methods to achieve this goal.300 Cell Stem Cell 6, April 2, 2010 ª2010 Elsevier Inc.There is cautious optimism about the possibility that methods
currently under development will produce cells resembling
pancreatic or islet progenitors from pluripotent cells like human
ESCs or iPSCs that can be used to replace b cells destroyed in
T1DM (D’Amour et al., 2006; Kroon et al., 2008; Zhang et al.,
2009). These methods attempt to recapitulate the sequence
of endogenous signaling pathways that first create progeny
cells resembling definitive endoderm, then ‘‘primitive’’ gut tube
epithelium, foregut pancreatic progenitors, islet progenitors
and, in the final step, hormone+ progeny including insulin+ cells.
It is sobering to reflect, however, that these methods are built on
developmental biology findings approaching or more than
a decade old and mainly reflect studies of nonmammalian or
rodent species. Below we review knowledge about human islet
development, highlighting areas we feel warrant attention. Prior
studies of pancreas and islet development in experimental
systems have carefully applied standard, powerful methods to
reveal molecular and cellular mechanisms underlying endoge-
nous islet cell differentiation, expansion, maturation, and func-
tion. However, such methods have not been systematically
applied to stem cell research efforts, and we suggest strategies
for doing so.
Prospects for Using Human Pancreas Developmental
Biology to Guide Islet Replacement
There has been rapid growth in our understanding of mecha-
nisms underlying pancreas development in the past two
decades, making it one of the best delineated among visceral
organs. Current strategies to generate replacement b cells
from pluripotent cell sources rely on knowledge of pancreas
and islet development derived largely from nonhuman experi-
mental models, including rats, chicks, and fish, but primarily
mice, and on the premise that cellular and molecular regulation
of pancreas development is conserved. In our view, an over
reliance on this premise is unwarranted, given apparent unique
features in the developmental programs governing human
pancreas and islet formation. The mouse pancreas has been
Table 1. Unestablished Fundamental Properties of Human Pancreas Development
Property Evidence from Nonhuman Studies
Bipotential endoderm capable of development toward hepatic
or pancreatic fates
Deutsch et al., 2001; Wandzioch and Zaret, 2009
Multipotent pancreatic progenitors marked and regulated by Pdx1,
Ptf1a, Sox9, and Cpa
Gu et al., 2002; Kawaguchi et al., 2002; Seymour et al., 2008;
Zhou et al., 2007
Cells expressing Ngn3 are monoclonal islet progenitors and their
development is regulated by the Notch signaling and other pathways
Gradwohl et al., 2000; Jensen et al., 2000; Apelqvist et al., 1999;
Desgraz and Herrera, 2009
Ngn3+ cells with limited proliferative capacity and their allocation
toward specific islet cell fates is regulated by intrinsic factors,
including Pax4 and Arx
Collombat et al., 2003; Collombat and Mansouri, 2009;
Sosa-Pineda, 2004
Expansion of pancreatic epithelial mass regulated by multiple
extrinsic factors, including Fgf10, Bmp, Wnt, Hedgehog, and Egf
reviewed by Murtaugh, 2007; Oliver-Krasinski and Stoffers, 2008
Expansion of b cells through enhanced proliferation wanes with age
and this is regulated by intrinsic factors including CyclinD1, D2, Ezh2,
Bmi1, p16/p18, Ir/Irs, p27, and FoxO
reviewed by Heit et al., 2006
Mechanisms thought to underlie pancreatic and islet development, principally in mice, are listed with supporting references.
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for identifying gaps in our knowledge about human pancreas and
islet development.
In mammals, the pancreas and other visceral organs like liver,
pharyngeal arch derivatives such as the parathyroids, and the
pulmonary organs develop from the definitive endoderm,
although lineage-tracing experiments establishing that the
pancreas arises from the endoderm have been performed only
in mice. Morphologically, the pancreas anlage emerges first
from dorsal then ventral mesenchymal condensations that
support evagination and branchingmorphogenesis of underlying
endoderm-derived epithelium in the posterior foregut. In both
mice and humans, fusion of the initially independent dorsal and
ventral pancreatic rudiments culminates in formation of a single
organ with mixed endocrine and exocrine functions that nestles
in the duodenal loop, which receives exocrine secretions
including bicarbonate and zymogens. Exocrine functions of the
pancreas originate in ductal and acinar cells, while endocrine
function derives from epithelial cell clusters called islets of Lang-
erhans. Distinct islet cells are defined by their principal hormone
product, including insulin in b cells and glucagon in a cells
(reviewed in Gittes, 2009). Host survival after autoimmune
destruction of b cells in T1DM requires insulin replacement.
Genetic studies in mice and humans have revealed conserved
regulators of pancreas development and islet cell function. For
example, homozygous recessive mutation of Pdx1 or Ptf1a,
which encode transcription factors initially expressed by epithe-
lial cells in the dorsal and ventral pancreatic anlagen, causes
pancreatic agenesis in mice and humans (Jonsson et al., 1994;
Krapp et al., 1998; Sellick et al., 2004; Stoffers et al., 1997b). In
humans, heterozygous mutations in Pdx1 or several other genes
(HNF1a, HNF1b, HNF4a, NeuroD1/Beta2, and Glucokinase)
result in b cell dysfunction and a condition known as maturity
onset of diabetes in the young (MODY), and in mice, recessive
mutations in these genes can also impair b cell function and
glucose regulation (reviewed in Fajans et al., 2001; Gittes, 2009).
Other features of mouse endoderm and pancreas development
revealed via classical embryology, genetic, and developmental
biology methods, including organ culture, loss-of-function
genetics, lineage tracing, and cell purification, have not yetbeen demonstrated to apply to human development (see
Table 1). Maturation of b cell functions governing energy sensing
and coupling of b cell detection of stimuli to insulin secretion
occurs in both fetal and postnatal stages in mammals, but regu-
lation of this process is poorly understood in all experimental
models. In mature b cells, evidence suggests that conserved
factors regulatemammalian insulin processing fromapropeptide
precursor and modulation of stimulus-secretion coupling during
b cell adaptation to physiological stresses like obesity, preg-
nancy, or normal host growth (Cozar-Castellano et al., 2006;
Heit et al., 2006).
Studies of early human organ development are generally
hindered by the limited accessibility to early human fetal tissues.
Thus, our knowledge of human pancreatic development is
largely based on a small number of studies involving retrospec-
tive immunohistological analysis of fixed tissues, gene expres-
sion profiling of bulk tissue, in vitro organ culture, or xenotrans-
plantation-based assessment of fetal pancreas (Castaing et al.,
2005; Lyttle et al., 2008; Piper et al., 2004; Polak et al., 2000;
Sarkar et al., 2008). Moreover, these studies are limited to a
narrow range of gestational ages (primarily weeks 7 through
21), precluding analysis of early cell-cell interactions and cell
fate decisions. Small numbers of tissue samples and different
experimental approaches further limit the statistical power of
conclusions from such studies. Addressing these deficiencies
will require new knowledge, including creation of methods to
isolate, profile, and characterize defined cell subsets from
human definitive endoderm and fetal pancreas (see below).
Although much of our knowledge of human pancreatic devel-
opment is based on prior studies in mice, it is clear that there are
fundamental differences between these two species that may
reflect differences in developmental mechanisms. For instance,
the morphology of the human and mouse pancreas differs at
both the organ and cellular level (Piper et al., 2004; Polak et al.,
2000). Unlike the mouse pancreas, which has an abundance of
mesenchymal cells, especially at the beginning of development,
the mesenchyme in fetal human pancreas is sparse and loosely
associated with the epithelial component. Thus, the quality
and nature of epithelial-mesenchymal interactions, which have
crucial, established roles in mouse pancreas specificationCell Stem Cell 6, April 2, 2010 ª2010 Elsevier Inc. 301
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stein, 1962; Wandzioch and Zaret, 2009), may be distinct in
human fetal pancreas. Islet b cells and non-b cells in rodents
like mice appear to segregate, but this segregation is less clear
in human (and nonhuman primate) islets. These morphological
differences may reflect both species-specific expression of islet
cell adhesion molecules like NCAM and Ep-CAM (Cirulli et al.,
1994, 1995, 1998, 2000) and the comparatively high proportion
of a cells in human versus mouse islets. These differences
between human and rodent islet architecture may have func-
tional consequences. For example, b cell oscillatory activity
(based on membrane depolarization) is not coordinated within
individual human islets as robustly as inmouse islets, and human
islets have been demonstrated to secrete insulin in response to
lower concentrations of glucose than rodent islets (Cabrera
et al., 2006).
The mechanisms regulating the speed and duration of islet
progenitor cell formation, progenitor maturation toward b cell
fates, and b cell replication may also be distinct in humans and
mice. In mice, fetal pancreas development occurs in 10 days,
and a period of accelerated b cell development (called the
‘‘secondary transition’’) and proliferation occurs in roughly the
latter half of gestation (reviewed in Gittes, 2009). There is
a lack of evidence for such punctuated b cell development in
humans (Sarkar et al., 2008). On the contrary, descriptive immu-
nohistology studies of human pancreatic morphogenesis (Jeon
et al., 2009; Lyttle et al., 2008; Piper et al., 2004; Polak et al.,
2000; Sarkar et al., 2008) suggest that the development process,
particularly for islets, spans several months. This difference is
further highlighted by the finding that ‘‘rescue’’ of experimental
diabetes by transplanted human fetal pancreatic tissue requires
a ‘‘maturation’’ period of up to 10 weeks (Hayek and Beattie,
1997). Do these distinctions reflect underlying differences in
the mechanisms governing islet development? Recent human
fetal pancreas studies of NGN3, amarker and essential regulator
of islet progenitor cell development in mice, support that possi-
bility.Ngn3mRNAexpression in the developingmouse pancreas
peaks around E15.5, roughly equivalent to week 7–8 (Carnegie
Stages 21–22) in human development. Consistent with this
timing and the hypothesis that human islet cells derive from
NGN3+ progenitors, human pancreatic cells expressing
hormones like insulin and glucagon emerge by 7–8 weeks, and
islet morphogenesis occurs continuously thereafter. However,
expression of NGN3 in the developing human pancreas is
prolonged and NGN3 mRNA peaks between weeks 11 and 19,
possibly reflecting the prolonged period of islet morphogenesis
and accumulation observed in a recent study by Jeon et al.
(2009). Unlike in islet cells in mice, NGN3 expression is readily
detectable by immunostaining in hormone+ cells (Wang et al.,
2009), suggesting that the regulation of NGN3 may differ in
humans and mice.
Mice harboring homozygous null Ngn3 mutations develop an
exocrine pancreas, including ducts and acini, but lack islets
(Gradwohl et al., 2000) as well as enteroendocrine cell subsets
(Lee et al., 2002). Recent studies pioneered by Martı´n and
colleagues (Wang et al., 2006) identified patients harboring
homozygous recessive alleles ofNGN3with aplasia of enteroen-
docrine cells (dubbed anendocrinosis) accompanied by congen-
ital diarrhea. These subjects had detectable serum insulin302 Cell Stem Cell 6, April 2, 2010 ª2010 Elsevier Inc.C-peptide perinatally and did not manifest neonatal diabetes,
providing evidence for development of islet b cells in these
subjects. Although some of these patients subsequently devel-
oped overt diabetes, treated by insulin replacement, these
collective findings raised the possibility that, unlike in mice, islet
development occurred in human subjects lacking NGN3. Subse-
quent studies suggested that the human NGN3 alleles linked to
congenital intestinal anendocrinosis were hypomorphic, not
null, alleles, but this remains controversial (Jensen et al., 2007).
Thus, definitive studies are required to establish the role of
NGN3 in human islet development.
Loss-of-function genetic studies were instrumental in estab-
lishing the roles of key regulators like Ngn3 in mouse pancreas
development. What are the prospects for such studies in human
pancreas developmental biology? Although genetic studies of
human pancreatic development remain highly constrained,
important opportunities for investigating developmental gene-
tics of human pancreas have been created by newer methods
like iPSC derivations from specific patients. Thus, we foresee
value in systematic analysis of cell lines derived from patients
harboring the heterozygous or homozygous mutations previ-
ously described (Table 2), coupled with studies of native fetal
pancreatic cells in vitro (see below). Such investigations could
prove useful for discovering the mechanisms that regulate
human pancreatic cell development, thereby defining the cellular
targets we hope to reconstruct from pluripotent cell sources.
Collectively, these considerations argue that intensified molec-
ular and cellular studies of pancreas development in humans
and in species with embryological homologies, including
simians, are warranted.
Methods for Deriving and Assessing Replacement Islet
Cells
The expansion of our knowledge about pancreas and islet devel-
opment, growth, and function stems in large part from incisive
use of standard tools in the developmental biology toolkit. These
include cell lineage tracing, cell purification, cell ablation, cell
mixing, mutant cell analysis, conditional genetics for gain- or
loss-of-function, organ reconstitution by cell transplantation,
and use of small molecule libraries. In the past several years,
many groups have adapted knowledge about the pancreas
and islets to attempt development of functional islet b cells or
their progenitors from renewable sources like ESCs or iPSCs
(D’Amour et al., 2006; Kroon et al., 2008; Zhang et al., 2009;
Borowiak et al., 2009) and from cell subsets from organs like
adult pancreas (Zhou et al., 2008). But, with very few exceptions,
these studies did not use the most powerful and precise devel-
opmental biology tools. Most frequently, cell cultures are
exposed to a sequence of factors or conditions culminating in
development of the desired cell type as aminor subset in amixed
population of cells. Typically, the frequency of factor or condition
changes is based somewhat arbitrarily on 8, 12, or 24 hr period-
icity. No prior study has achieved resolution of the heterogeneity
at the final ‘‘stages’’ of in vitro differentiation by cell sorting or
other methods. To our knowledge, lineage tracing studies have
also not been reported. It therefore remains unknown whether,
for example, cells thought to resemble endoderm from the
expression of SOX17 protein engender progeny in the next
stages that resemble pancreatic progenitors expressing PDX1,
Table 2. Genetic Regulation of Human Pancreatic Development and Islet Function
Gene Phenotype References
PDX1 homozygous: congenital pancreatic agenesis; heterozygous: monogenic diabetes
(MODY4) and type II diabetes
Stoffers et al., 1997a, 1997b
PTF1A homozygous: pancreatic and cerebellar agenesis Sellick et al., 2004
SOX9 heterozygous: campomelic dysplasia, pancreatic malformation Foster et al., 1994
NEUROD1 heterozygous: monogenic diabetes (MODY6) Malecki et al., 1999
NGN3 homozygous: congenital malapsorptive diarrhea, intestinal anendocrinosis, diabetes Wang et al., 2006
GCK homozygous: persistent neonatal diabetes; heterozygous: monogenic diabetes (MODY2) Njølstad et al., 2001; Vionnet et al., 1992
HNF1a heterozygous: monogenic diabetes (MODY3) Yamagata et al., 1996
HNF1b heterozygous: monogenic diabetes (MODY5); cystic kidney disease Horikawa et al., 1997
HNF4a heterozygous: monogenic diabetes (MODY1) Fajans, 1989
MEN1 heterozygous: multiple endocrine neoplasia Chandrasekharappa et al., 1997
CDKN1B heterozygous: multiple endocrine neoplasia Pellegata et al., 2006
CDKN2C heterozygous: multiple endocrine neoplasia Agarwal et al., 2009
ARX hemizygous males: lissencephaly, epileptic encephalopathy, abnormal genitalia Kitamura et al., 2002
PAX4 heterozygous: monogenic diabetes (MODY9) Plengvidhya et al., 2007
GLIS3 homozygous: neonatal diabetes and congenital hypothyroidism Sene´e et al., 2006
KCNJ11 homozygous: hyperinsulinemic hypoglycemia; heterozygous: persistent neonatal diabetes Thomas et al., 1996; Gloyn et al., 2004
RFX6 homozygous: neonatal diabetes, pancreatic hypoplasia, intestinal atresia,
and gall bladder aplasia or hypoplasia
Smith et al., 2010
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produced in culture experiments is not established. Thanks to
the widespread use of homologous recombination to produce
‘‘reporter’’ cells, sequential lineage tracing with lineage-marking
methods based on, for instance, Cre-recombinase, is well within
reach for mouse ESC and iPSC studies. However, enhance-
ments of methods for gene targeting by homologous recombina-
tion (Porteus and Baltimore, 2003; Zou et al., 2009; Zwaka and
Thomson, 2003) are needed to foster this approach in human
ESC and iPSC lines. Direct isolation of enriched cell subsets
followed by ‘‘replating’’ and continuation of development may
act as a surrogate for lineage-tracing experiments. Yasunaga
et al. (2005) described replating mouse ESC progeny isolated
by FACS for the Cxcr4 antigen to differentiate endoderm-like
cells, but to our knowledge, this general approach has not
been used in attempts to produce islet or pancreas-like cells
from ESC lines (Figure 1B). By contrast, similar studies aiming
to produce functional cardiomyocytes or cardioblasts have fruit-
fully used such approaches (Bu et al., 2009; Yang et al., 2008). It
is therefore not surprising that maturation of functional glucose-
sensing cells resembling islet b cells from prior in vitro approxi-
mations of pancreatic islet development has not been achieved
(Kroon et al., 2008). Below, we discuss cell purification, lineage
tracing, and genetic strategies for enhancing attempts to control
the complex programs underlying development of islet-like cells
from renewable or expandable human cell sources.
What Is the Lineage and Quality of Pluripotent
Stem Cell Progeny?
Studies of gene expression in FACS-purified native cardiomyo-
cyte and hematopoietic progenitor/stem cell lineages has
accelerated experimental attempts to generate these cells
from cultured hESCs and iPSCs (Bu et al., 2009; Yang et al.,
2008). Even without such precedents, it seems self-evidentthat an understanding of fundamental phenotypes of native
pancreatic cells, like gene expression profiles and cell surface
markers for FACS, would enhance cell culture-based efforts to
produce cells resembling them; just what are we trying to
make in our experiments? There is a slowly accumulating body
of data on gene expression in isolated cell subsets from the
developing and postnatal mouse pancreas, but these data focus
largely on mature b cells (Gu et al., 2004; White et al., 2008).
Moreover, some gene expression profiles may unfortunately be
‘‘contaminated’’ because of imprecisely defined experimental
strategies to label and sort relevant cells. For example, perdur-
ance of the eGFP signal derived from a Ngn3-eGFP transgene
led to labeling of both Ngn3+ hormone– islet progenitors and
their hormone+ progeny, including Insulin+ b cells (Sugiyama
et al., 2007). Thus, gene expression profiles ofNgn3-eGFP+ cells
(Gu et al., 2004) may reflect this mixture of cells.
Analysis of purified native cell subsets from definitive endo-
derm, primitive gut tube, foregut, the developing pancreas,
and associated organs like the liver may help to define pathways
that regulate cell differentiation, growth, survival, and other
phenotypes. Such studies may also reveal novel gene interac-
tions or developmental or islet cell maturation regulators, and
may identify cell surface markers for FACS purification of cell
subsets, independent of genetic background (Gadue et al.,
2009; Sugiyama et al., 2007; Xu et al., 2008). Although
genomic-scale studies for isolated rat a and b cells have been
reported (Kutlu et al., 2009), the majority of studies using
methods like DNAmicroarrays have focused onwhole pancreas,
islets, or immortalized islet cell lines (White and Kaestner, 2009)
in model organisms such as rodents. The lone genomic-scale
study of human fetal pancreatic gene expression described
results from analysis of whole pancreatic tissue (Sarkar et al.,
2008). Thus, development of methods for isolating native
pancreatic and islet progenitor cells will be crucial for advancingCell Stem Cell 6, April 2, 2010 ª2010 Elsevier Inc. 303
Figure 1. Schematic Summarizing Two General Strategies to Assess and Improve the Quality of Progeny Produced from Pluripotent Stem
Cell Cultures
(A) Marking of embryonic stem cell (ESC) or induced pluripotent stem cell (iPSC) progeny via Cre recombinase-based methods to induce expression of probes
signaling sequential passage through a SOX17+, then NGN3+ and INSULIN+ fates. n1, n2, and n3 represent numbers of indicated, undifferentiated, or partially
differentiated cells in cultures, where n1 < n2 < < n3.
(B) Sequential flow cytometry-based enrichment to reduce heterogeneity of ESC or iPSC progeny at discrete stages of differentiation toward SOX17+,
then NGN3+ and INSULIN+ fates.
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and experimental animals (Figure 1B). Recently, Grompe and
colleagues used a ‘‘decoy’’ strategy to identify monoclonal anti-
bodies for fractionating and isolating human islet and exocrine
cell subsets from adult human pancreas (Dorrell et al., 2008),
but additional studies are needed to test whether these reagents
will also permit sorting of human fetal pancreatic cell subsets.
Flow cytometry-based purification methods for developing
cell subsets in the fetal human pancreas could significantly
enhance outcomes of tissue differentiation studies from ESC
or iPSC sources. For example, flow cytometry strategies could
be used to isolate specific cell subsets for analysis and resolve
undesirable cell heterogeneity; this in turn could prevent hazards
like formation of teratomas or other tumors known to arise from
ESC and iPSC types (Takahashi et al., 2007). Isolation of cells
expressing native surface markers would also impose a type of
‘‘quality control’’ on in vitro culture methods; for example, cells
produced from ESC cultures could be enriched for cell progeny
with greater similarity to endogenous cells. Such an approach
was recently used to isolate cardioblast-like cells from ESC
cultures by Keller and colleagues (Yang et al., 2008). Undifferen-
tiated ESCs may express cell surface markers that would other-
wise serve to fractionate progeny, thereby limiting use of some
antigens for these approaches. For example, CD133 (also known
as prominin) is well established as a marker of endogenous
stem or progenitor cell populations in neural, hematopoietic,
skin, and pancreatic lineages. However, undifferentiated mouse
and human ESCs express high levels of CD133 (Kania et al.,304 Cell Stem Cell 6, April 2, 2010 ª2010 Elsevier Inc.2005), precluding use of this marker for studies in the early
stages of in vitro ESC developmental studies. Yet, if CD133 is
downregulated during initial stages of differentiation and subse-
quently reexpressed, it could be combined with other cell
surface antigens to isolate in vitro-derived pancreatic progenitor
cells. Also, although dissociation of epithelial cells is possible,
flow cytometric analysis of epithelial cells is often complicated
by eventual cell death from anoikis and other mechanisms
(Alexander et al., 2009). Thus, although isolation and replating
of mesodermal or mesenchymal cells has been described
(Yang et al., 2008), purification and replating schemes like that
outlined in Figure 1 have been difficult to achieve with epithelial
lineages derived fromESC cultures. However, an armory of other
fruitful approaches based on cell separation by magnetic beads
or by immunopanning, which has been used to overcome the
challenge of isolating neural cell subsets like astrocytes or
projection neurons (Dugas et al., 2008), could be applied more
broadly to epithelial differentiation schemes and combined
with methods that increase cell-cell interactions, like sphere
culture (Seaberg et al., 2004). Alternately, depletion of cells via
selection with drugs like blasticidin, G418, or hygromycin
combined with lineage-specific activation of drug-resistance
markers is a strategy that can be used to avoid the need for
dispersion-based cell isolation (Kawaguchi et al., 2010). Such
drug selection-based cell enrichment schemes may also help
to address an unanswered fundamental question in derivation
of specific cells from ESC and iPSC cultures: is the cell heteroge-
neity inherent to these cell cultures required for derivation of
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to address this question may require systematic removal of
specific cell subsets from heterogeneous cultures, which might
be facilitated by drug selection schemes.
Interrogating the Quality of Stem Cell Progeny
with Genetics
Emerging data on gene expression and epigenetic profiles
should prove useful for evaluating cell products of ESC or
iPSC cultures. To date, the Food and Drug Administration, which
oversees cell replacement therapy safety in the US, has not
required expression profiles of key genes or analysis of the
epigenome in these cellular products. However, once this sort
of evaluation has been performed and validated, it may be
extremely helpful in characterizing or improving cell populations.
For example, Mutskov and Felsenfeld (2009) recently reported
unique features of the epigenetic ‘‘landscape’’ of the INSULIN
gene locus in human cells.We envisage that fine-scalemolecular
mapping of epigenetic regulation at native loci encoding hall-
mark b cell factors like INSULIN could help validate candidate
cell populations produced from ESC or other stem cell cultures.
To supplement corroborative, descriptive studies of gene
expression and epigenetic status, loss-of-function genetics
can provide powerful ways to interrogate the quality of these
cell products. For example, genes likeSox17, Pdx1, other MODY
genes, and established key regulators like Ptf1a, Sox9, and
Ngn3 have been modified to create conditional null alleles in
mice and mouse ESC lines (Kawaguchi et al., 2002; Gu et al.,
2002; Seymour et al., 2007). Prior in vivo studies after inactivation
with Cre recombinase have permitted identification of products
encoded by these genes as key developmental regulators of
definitive endoderm, foregut epithelium, pancreatic progenitors,
and insulin-secreting b cells. Likewise, studies of regulators like
Men1, p27Kip1, p18INK4c, Ezh2, and Bmi have permitted identifi-
cation of key functions in mature b cells regulating chromatin
dynamics, proliferation, and fate control (Chen et al., 2009;
Crabtree et al., 2001; Dhawan et al., 2009). Thus, loss-of-func-
tion analysis of these well-studied loci would provide important
genetic benchmarks for comparing progeny from in vitro cultures
to native cellular counterparts formed during normal organogen-
esis. For example, islet development is blocked in mice lacking
Ngn3, and this phenotype is recapitulated in some culture
methods (Sugiyama et al., 2007); however, inactivation of Ngn3
has not been used to validate current methods for generating
hormone+ cells from any ESCs or iPSCs (Borowiak et al., 2009;
D’Amour et al., 2006; Kroon et al., 2008; Zhang et al., 2009).
Moreover, genetic resources in human ESC and iPSC lines
are still in an early stage of development. Systematic use of
genomic-scale RNAi resources might provide another means
for analysis, but current methods based on this approach re-
main limited by incomplete or inconsistent loss of function and
technical challenges in transplantation-based settings. Thus,
although we emphasize the importance of human pancreatic
studies here, there are clear opportunities for exploiting existing
(but underused) genetic resources from organisms like mice.
Development of similar resources in human pluripotent cells,
including iPSC lines, could be facilitated by prior identification
of patients with pancreatic or diabetic phenotypes linked to
mutant alleles, including null alleles, in IPF1/PDX1, HNF1a,HNF1b, HNF4a, GLUCOKINASE, NEUROD1/BETA2, SOX9,
NGN3, PTF1A, MEN1, and other genes (Table 2).
Assays of Developmental Potential
Developmental and stem cell biologists attempting to reconsti-
tute organogenesis in vitro are challenged by the knowledge
that many features of endogenous developmental signaling
may not be recapitulated in their culture systems (Huppert and
Magnuson, 2009; Wandzioch and Zaret, 2009). Reconstitution
of cell-cell interactions by cell mixing may improve attempts to
recapitulate some aspects of cell-cell signaling. For example,
coculture of pancreatic epitheliumwith vascular endothelial cells
may recapitulate aspects of early signaling coordinating in vivo
pancreas development (Lammert et al., 2001; Yoshitomi and
Zaret, 2004). However, developmental cell fates in the pancreas
probably result from a series of transient, complex cell-cell
interactions and other signaling events in a three-dimensional
space, whose elements have not yet been reconstituted. Thus,
inefficiencies are probably inherent to in vitro approaches that,
ultimately, are mere molecular approximations of the actual
development programs. Ultimately, preclinical assessment of
developmental potential and physiological function will depend
on imaginative use of in vitro systems that approximate native
stem/progenitor cell niches (Lutolf et al., 2009), and for human
ESC or iPSC progeny, xenotransplantation-based assays. For
subsets of cells in the pancreatic or islet lineage, however,
current methods for assaying developmental potential are
limited, with themajority of in vivo studies employing heterotopic
graft sites like the renal subcapsular space or omentum of SCID
or NOD scid mouse hosts (D’Amour et al., 2006; Kroon et al.,
2008).
These assays constitute a kind of ‘‘graft and hope’’ approach
that limits interpretation, especially in the analysis and quantifi-
cation of developmental phenotypes. To assess the develop-
mental potential of native mouse pancreatic Ngn3+ cells, we
surveyed multiple culture conditions and found that insulin+
and glucagon+ cells developed when Ngn3+ islet progenitors at
low density were cocultured either with mitomycin C-treated
mouse embryonic fibroblasts (MEFs) or with PA6 mouse stromal
cells, a feeder cell layer shown to promote neural differentiation
by embryonic stem cells (Kawasaki et al., 2000). Although the
coculture assays helped confirm the developmental potential
of isolated Ngn3+ cells to form b cells and other islet cells
(Sugiyama et al., 2007), they also had limitations. Specifically,
there was poor survival of input pancreas cells, measured to
be about 0.01%–0.05% after 3 days’ culture, and no evidence
of cell proliferation. Heimberg and colleagues recently reported
use of Ngn3 mutant fetal mouse pancreas as a platform for as-
sessing developmental properties of injected mouse Ngn3+ cells
(Xu et al., 2008). Use of specific feeder cells or surrogate niches
like fetal pancreas is an approach that could be extended to
in vivo assays of developmental potential. The lack of a ‘‘reconsti-
tution’’ assay analogous to bone marrow transplantation is
impeding attempts to isolate and assess candidate progenitor
cells derived from ESC and iPSC sources for visceral organs
like the pancreas and islet progenitor cells. This is a major limita-
tion inmany fields, not just pancreas biology, and restricts efforts
to use, for example, genetic screens to discover regulators of
islet maturation or proliferation. We speculate that sites in organsCell Stem Cell 6, April 2, 2010 ª2010 Elsevier Inc. 305
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Perspectivewith native endocrine and exocrine tissues that support islet
engraftment, like adult pancreas (Hayek and Beattie, 1992) or
mammary stroma (Outzen and Leiter, 1981), as well as experi-
mentally modified sites (Dufour et al., 2005) could be explored
as potential surrogate niches for developmental studies of
pancreatic and islet progenitor cells.Summary
Bone marrow transplantation (BMT) remains a bewitching para-
digm of cell-based therapy for biomedical researchers. BMTwas
originally applied as an experimental therapy several decades
ago for patients with diseases like chronic myelogenous
leukemia in blast crisis, who could otherwise expect to live
for an average of only 6 weeks. By contrast, the stakes for
cell-based therapies in T1DM have been heightened by the
transformation of this once rapidly fatal disease, through insulin
replacement and other treatment advances, into a chronic illness
with an average patient lifespan of more than six decades. As
a result, any cell-based therapy for diabetes would need to
have a high benefit to risk ratio. Rigorous application of standard
molecular methods to studies of pluripotent cells will probably
both accelerate production of functionally superior islet replace-
ment cells and enhance the safety of such cells. For example, the
risk of tumor development from pluripotent cell sources in immu-
nosuppressed patients must be eliminated. However, current
claims of reduced or eliminated potential of ESC- or iPSC-
derived progeny to form tumors like teratomas made in prior
studies are problematic for at least two reasons. First, there is
a manifest need to transplant large numbers of cells (whether
‘‘progenitors’’ or more differentiated insulin-secreting cells) to
replace islet function in patients with T1DM; however, such large
numbers have not be generated or transplanted in any prior
study, to our knowledge. Second, the establishment and pro-
longed maintenance of appropriate genetic and epigenetic
regulation in cells produced from ESCs or iPSCs has not been
demonstrated. In our view, this is an important practical mile-
stone, because of the established role of reduced gene dosage
or expression of tumor suppressor loci encodingMen1, p27Kip1,
and p18Ink4c in pathogenesis of human endocrine tumor
syndromes (reviewed in Agarwal et al., 2009). However, no study
has yet determined whether ‘‘appropriate’’ expression of these
known regulators of growth and cell fate, and their molecular
targets, exists in the progeny of stem cell cultures.
‘‘Regenerative medicine’’ has become a common phrase that
expresses more hope than experience. Prior studies and
evidence argue that considerable further progress is required
before such a title can be earned and applied to stem cell
approaches for the treatment of diabetes. However, armed
with powerful experimental approaches, we and others remain
undaunted by this challenge.ACKNOWLEDGMENTS
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